Clinical trials: Adaptive Immunity
Malaria
Age of Exposure and Immunity to Malaria in Infants
The overall objective is to evaluate the effect of exposure to Plasmodium (P.) falciparum erythrocytic stage antigens during different periods of infancy on the development of naturally acquired immunity (NAI).
- Trial name
- NCT00231452
- Testing
- Sulfadoxine-pyrimethamine (SP) + Artesunate (AS)
- Where
- Mozambique
- Volunteers
- 349 people, healthy volunteers welcome
- Sponsor
- Hospital Clinic of Barcelona
Children With Cancer, SARS-CoV-2 Infection
Persistent SARS-CoV-2 Infection in Children With Cancer and Impaired Immune Responsiveness
The main goal of this study is to characterize the adaptive immune responses to SARS-CoV-2 infection in a cohort of children with cancer and impaired immune responsiveness and prolonged viral shedding of SARS-CoV-2, and to…
- Trial name
- NCT05172063
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Children's Cancer Hospital Egypt 57357
Advanced / Metastatic Solid Tumors, Advanced Malignancy
Immunotherapy Master Trial for Advanced Cancers
Over the past decade, cancer immunotherapy has profoundly transformed oncology by harnessing the patient's immune system to target tumors.
- Trial name
- METAREM (NCT07431073)
- Testing
- METAREM is a master protocol that encompasses multiple therapeutic sub-protocols, each involving distinct interventions. Accordingly, the description of the intervention will be specified within each
- Where
- France
- Volunteers
- 275 people
- Sponsor
- UNICANCER
Transplant, Adaptive Immunity
CNTRP POSITIVE Study
Adequate control of immunosuppression is critical in preventing graft failure after solid organ transplantation (SOT) and in avoiding life-threatening viral and malignant complications.
- Conditions
- Transplant, Adaptive Immunity, EBV, Medication Adherence
- Trial name
- NCT02318030
- Where
- Canada
- Volunteers
- 600 people
- Sponsor
- The Hospital for Sick Children
COVID-19 Infection
Send-In Sample Collection for Comprehensive Analyses of Innate and Adaptive Immune Responses During Acute COVID-19 and Convalescence
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19). The global outbreak of COVID-19 is a major public health problem. COVID-19 causes a wide range of symptoms.
- Trial name
- NCT04582903
- Where
- United States
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Antibiotic Resistance Prevention
Assessing the Impact of Unnecessary Antibiotic Treatment on the Development of Appropriate Adaptive Immune Responses in Malnourished Bangladeshi Infants
The investigators are examining the role of circulating T follicular helper (Tfh) cells in the induction of the antibody responses.
- Trial name
- NCT07615842
- Testing
- Azithromycin
- Where
- Bangladesh
- Volunteers
- 150 people
- Sponsor
- University of Virginia
Immunodeficiencies, Immune Dysregulations
COVID-19 Vaccination and Outcomes in Individuals With and Without Immune Deficiencies and Dysregulations
Background: The immune system defends the body against disease and infection. Immune deficiencies are health conditions that decrease the strength of this response.
- Trial name
- PERSIST (NCT04852276)
- Where
- United States
- Volunteers
- 308 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Childhood Pneumonia, Mycoplasma Pneumonia
Evaluation of Pathogenesis and Diagnosis of Mycoplasma Pneumoniae Community-acquired Pneumonia (CAP)
To investigate the Mycoplasma pneumoniae-specific circulating antibody-secreting cell (ASC) response and Mycoplasma pneumoniae-specific interferon (INF)-γ-secreting T cell response, along with polymerase chain reaction (PCR) and…
- Conditions
- Childhood Pneumonia, Mycoplasma Pneumonia, Antibody-secreting Cells, Enzyme-linked Immunospot (ELISpot)
- Trial name
- myCAP (NCT03613636)
- Testing
- Enzyme-linked immunospot (ELISpot) assay [Blood]
- Volunteers
- 490 people, healthy volunteers welcome
- Sponsor
- University Children's Hospital, Zurich
Malaria
Correlates of Protection in Ghana
Malaria is a sickness passed from one person to the other by the bite of a mosquito. In areas of frequent malaria infection, children may develop natural protection against malaria and they are less likely to become sick or die…
- Trial name
- NCT00138307
- Where
- 2 sites in Ghana
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza, Healthy
The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection
The purpose of this study is provide a better understanding of the adaptive immune response to the licensed influenza vaccines in children.
- Trial name
- SLVP030 (NCT03453801)
- Testing
- Fluzone®, FluMist®
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Stanford University
Malaria, Falciparum
Malaria Transmission Studies in Mali
Background: Malaria is an illness caused by a parasite spread by mosquitoes. When a mosquito bites a person who is infected with a kind of parasite called a gametocyte, it is able to spread the infection to another person.
- Trial name
- NCT01829737
- Where
- United States
- Volunteers
- 534 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Epithelial High Grade Serous Ovarian Cancer
Elements of Adaptive Immunity in Epithelial Ovarian Cancer
The study seeks to evaluate the presence and correlation with clinical outcome of several components of adaptive immunity (TILs, TLS, plasma cells and PD-L1 expression) in tumor specimens of patients with EOC treated with…
- Trial name
- NCT07528911
- Testing
- Assessment of elements of adaptive immunity in tumor biopsies
- Where
- Greece
- Volunteers
- 687 people
- Sponsor
- Hellenic Cooperative Oncology Group
Respiratory Syncytial Virus (RSV), Respiratory Infection Virus
THRIVE - Trial of Passive Humoral RSV Immunity for Value and Effectiveness
RSV is a leading cause of severe respiratory illness and hospitalisation for young children, with particularly high rates of RSV respiratory infection observed amongst Aboriginal and Torres Strait Islander children living in…
- Trial name
- THRIVE (NCT07578298)
- Testing
- Nirsevimab (RSV-specific monoclonal antibody)
- Where
- Australia
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Menzies School of Health Research
SARS CoV 2 Infection, SARS CoV 2 Vaccination
COVID-19 Transmission and Morbidity in Malawi
SARS-CoV-2 transmission was expected to have a devastating impact in sub-Saharan African countries. Instead, morbidity and mortality rates in nearly the whole region are an order of magnitude lower than in Europe and the…
- Trial name
- COVID-TMM (NCT05973084)
- Where
- 2 sites in United States, Malawi
- Volunteers
- 1,500 people
- Sponsor
- Boston University
Influenza
Innate and Acquired Immunity to Influenza Infection and Immunization (SLVP029)
The purpose of the study is to get a better understanding of the natural and adaptive immune response to the flu virus and to compare the immune cell responses to FDA-licensed flu vaccines in nasal mucosal cells and in blood.
- Trial name
- NCT03028974
- Testing
- Fluzone®, FluMist®
- Where
- United States
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Stanford University
Malaria, Filarial Infection
Immune Response Regulation in People Infected Concurrently With Malarial and Filarial Parasites
This study, conducted by NIH and the University of Bamako in Mali, Africa, will study the effect of concurrent infections with malaria and filariasis on patients' immune response.
- Trial name
- NCT00341666
- Where
- Mali
- Volunteers
- 360 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Localized Cancer
Neo-adjuvant Immunotherapy Master Trial for Localized Cancers
Most cancer treatments are developed without knowing whether the drug's targets are actually present in a patient's tumor or whether the patient is likely to benefit from the treatment.
- Trial name
- NEOREM (NCT07262489)
- Testing
- Each therapeutic NEOREM sub-protocol will mention the description of intervention
- Where
- France
- Volunteers
- 200 people
- Sponsor
- UNICANCER